Blair Brengle
Family Medicine · Indianapolis, INNPI 1023014420
Payments from drug & device makers
Across 1,037 payments — averaging $10,178 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$8.1M
- Sanofi Pasteur Inc.$2.4M
- Novartis$30K
- Novo Nordisk AS$29K
- Sanofi$17K
- Cue Health Inc.$10K
- plus $9K from 24 others
Across 39 payments — averaging $42,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.7M
- Sanofi Pasteur Inc.$2K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$8,60050%
- Travel & lodging$2,04712%
- Food & beverage$6,29737%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 78 | $8,089,290 |
| Sanofi Pasteur Inc. | 64 | $2,371,314 |
| Novartis | 26 | $29,534 |
| Novo Nordisk AS | 610 | $28,661 |
| Sanofi | 2 | $17,165 |
| Cue Health Inc. | 1 | $9,919 |
| Sanofi US Services Inc. | 2 | $3,300 |
| Novo Nordisk | 71 | $1,471 |
| AbbVie(2 entities) | 52 | $1,211 |
| Lilly USA, LLC | 43 | $855 |
| Bayer | 12 | $252 |
| Harmony Biosciences LLC | 5 | $161 |
| Pfizer | 9 | $159 |
| Astellas Pharma US Inc | 7 | $133 |
| Currax Pharmaceuticals LLC | 9 | $121 |
| Amgen | 6 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $91 |
| AstraZeneca | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| GSK | 3 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Abbott | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Merz North America, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,554,412 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $43,187 |
| OzempicSemaglutide | 38 | $40,074 |
| EntrestoSacubitril/Valsartan | 24 | $32,834 |
| EliquisApixaban | 29 | $18,592 |
| RybelsusSemaglutide | 19 | $17,857 |
| FarxigaDapagliflozin Propanediol | 11 | $16,438 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $5,440 |
| Nebivolol Hcl | 17 | $1,688 |
| Pregabalin | 13 | $882 |
| Codeine Sulfate | 13 | $882 |
| Tramadol Hcl | 21 | $814 |
| Insulin Degludec Pen (U-200)Insulin Degludec | 11 | $769 |
| Metoprolol Succinate | 29 | $657 |
| Atorvastatin Calcium | 84 | $653 |
| Mirtazapine | 17 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,471 | $57,93157 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $855 | $43,73148 claims |
| NovartisEntresto | $29,534 | $32,83424 claims |
| PfizerEliquis | $159 | $18,59229 claims |
| AstraZenecaFarxiga | $84 | $16,43811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
- Laura HelmanMishawaka$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.